Drug Database · Clinicians

Tinzaparin

Brands (1) InnohepShow all

Antithrombotic agents PH FDA category

Treatment dose: not advised if CrCl <30Rx · Prescription drug1 PH productPNF-listed Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals

Contraindications

  • Current or past immune heparin-induced thrombocytopenia
  • Active major bleeding or high bleeding risk
  • Septic endocarditis
  • Treatment doses with neuraxial anesthesia
  • Hypersensitivity
renalcarematters.com, reviewed

Dosing: Adult

  • Treatment of deep vein thrombosis and pulmonary embolism: 175 anti-Xa IU/kg SC once daily for at least 6 days and until oral anticoagulation is established
  • Extended treatment of cancer-associated venous thromboembolism: 175 anti-Xa IU/kg SC once daily for 6 months; reassess beyond
  • VTE prophylaxis, surgery: 3,500 IU SC 2 hours before surgery (moderate risk) or 4,500 IU 12 hours before (high risk), then once daily while at risk
  • VTE prophylaxis, acute medical illness: 3,500 IU (moderate risk) or 4,500 IU (high risk) SC once daily while at risk
  • Hemodialysis circuit: See the kidney panel
renalcarematters.com, reviewed

Dosing: Altered kidney function

Tinzaparin is a low-molecular-weight heparin cleared mainly by the kidneys but with significant non-renal elimination; the Irish label reports no accumulation down to creatinine clearance (CrCl) 20 mL/min. For venous thromboembolism treatment (175 IU/kg once daily) it is not recommended below CrCl 30 mL/min; if used, anti-factor Xa levels guide the dose. It has no current US FDA label.

Kidney function measure: Irish summary of product characteristics (SmPC) uses creatinine clearance (CrCl, mL/min).

Show full dosing details
CrCl ≥60 mL/min
Treatment: 175 anti-Xa IU/kg SC once daily (rounded in 1,000 IU steps) for at least 6 days and until oral anticoagulation is adequate; cancer-associated VTE: 6 months (SmPC).
CrCl 30–59 mL/min
No dose change at CrCl ≥30 (SmPC). No accumulation seen down to CrCl 20 in older adults.
CrCl 15–29 mL/min
Not recommended (dose not established). If needed and the benefit outweighs the risk, start with anti-factor Xa (anti-Xa) monitoring 4 to 6 hours after a dose and repeat after 3 to 4 doses (for guidance, 0.5 to 1.5 IU/mL in patients without severe impairment) (SmPC). In adults 70 years and older with kidney impairment, the IRIS trial stopped early for higher mortality with tinzaparin than unfractionated heparin (unexplained; anti-Xa did not accumulate); unfractionated heparin is a reasonable alternative.
CrCl <15 mL/min (not on dialysis)
Not recommended (dose not established). If needed and the benefit outweighs the risk, start with anti-factor Xa (anti-Xa) monitoring 4 to 6 hours after a dose and repeat after 3 to 4 doses (for guidance, 0.5 to 1.5 IU/mL in patients without severe impairment) (SmPC). In adults 70 years and older with kidney impairment, the IRIS trial stopped early for higher mortality with tinzaparin than unfractionated heparin (unexplained; anti-Xa did not accumulate); unfractionated heparin is a reasonable alternative.
Hemodialysis (intermittent)
Circuit anticoagulation (labeled): session of 4 hours or less, 2,000 to 2,500 anti-Xa IU as a bolus at the start of dialysis; session longer than 4 hours, 2,500 IU bolus then 750 IU/hour as a continuous infusion; adjust the bolus in 500 IU steps (usual 2,000 to 4,500 IU) (prophylaxis/hemodialysis SmPC). Treatment doses for VTE are not recommended (CrCl <30); if used, anti-Xa-guided. Half-life about 2.5 hours after an IV bolus in dialysis patients.
Peritoneal dialysis
Treatment doses not recommended (CrCl <30); if used, anti-Xa-guided.
CRRT
Not recommended at treatment doses; if used, anti-Xa-guided. Unfractionated heparin is usually preferred.
  • Dialyzable? Not stated.
  • Monitoring Anti-Xa (0.5 to 1.5 IU/mL 4 to 6 hours after dose) if used at CrCl <30. Platelets before and during treatment (heparin-induced thrombocytopenia). Potassium in diabetes, chronic kidney failure and metabolic acidosis (hypoaldosteronism). Neuraxial anesthesia timing (SmPC 4.2, 4.4).
Children (kidney dosing)
eGFR ≥60
Not established in children; kidney dosing not applicable.
eGFR 30–59
Not established in children; kidney dosing not applicable.
eGFR 15–29
Not established in children; kidney dosing not applicable.
eGFR <15 (not on dialysis)
Not established in children; kidney dosing not applicable.
Hemodialysis (intermittent)
Not established in children; kidney dosing not applicable.
Peritoneal dialysis
Not established in children; kidney dosing not applicable.
CRRT
Not established in children; kidney dosing not applicable.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

Source: HPRA (Ireland) product information (November 2024). This generic has no US FDA label.

Dosing: Pediatric

Approved ages
Not established under 18 years (SmPC).
Usual dose
Not established.

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed

Dosage forms

Registered products in the Philippines

1 product registered with the Food and Drug Administration (FDA) Philippines list Tinzaparin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

Philippine FDA-registered products for Tinzaparin
Package insert
InnohepTinzaparin Sodium
10000 anti-Xa IU/mL Solution For Injection (SC)2 mL colorless glass Type I vial with bromobutyl rubber stopper and aluminum cap (Box of 10's)
Rx
Leo Pharma A/SDenmark
Getz Bros. Philippines, Inc.
BR-1080
Dec 12, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Drug interactions

Drug or classSeverityEffectWhat to do
Antiplatelets, NSAIDs, thrombolytics, vitamin K antagonists, other anticoagulantsAdjust or monitorMore bleeding.Avoid or monitor closely.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed

Adverse reactions

Common

  • Bleeding
  • Anemia
  • Injection-site reactions

Serious

  • Major hemorrhage
  • Heparin-induced thrombocytopenia (immune)
  • Spinal or epidural hematoma with neuraxial anesthesia
  • Hyperkalemia (hypoaldosteronism)
  • Anaphylaxis, skin necrosis, Stevens-Johnson syndrome
renalcarematters.com, reviewed

Monitoring parameters

  • Anti-Xa (0.5 to 1.5 IU/mL 4 to 6 hours after dose) if used at CrCl <30. Platelets before and during treatment (heparin-induced thrombocytopenia). Potassium in diabetes, chronic kidney failure and metabolic acidosis (hypoaldosteronism). Neuraxial anesthesia timing (SmPC 4.2, 4.4). Kidney
  • Platelets
  • Potassium in at-risk patients
  • Anti-Xa if CrCl <30
renalcarematters.com, reviewed

Pharmacokinetics

Key PK parameters

BioavailabilityAbout 90% (SC)
Time to peak4 to 6 hours
Half-lifeAbout 3.7 hours
Half-life in kidney failure (ESKD) kidneyAbout 2.5 hours after an IV bolus in dialysis patients; no accumulation down to CrCl 20
Metabolism (CYP, transporters)Minor hepatic depolymerization
Renal excretion kidneyMainly renal (unchanged or nearly unchanged), with significant non-renal elimination
Dialyzability kidneyNot stated
renalcarematters.com, reviewed

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Tinzaparin 10,000 anti-XA IU/mL, 0.45 mL pre-filled syringe₱238.31per syringeDPRI reference price
Tinzaparin 10,000 anti-Xa IU/mL, 2 mL vial₱711.57per vialDPRI reference price

Reference price based on the Maximum Wholesale Price (MWP); excluded from the 10% inflation allowance

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Tinzaparin (as sodium)
PNF listingInj.: 10,000 anti-Xa IU/mL, 0.35 mL and 0.45 mL pre- filled syringe (SC)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2)
PNF listingInj.: 10,000 anti-Xa IU/mL, 2 mL vial (SC)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Health Products Regulatory Authority (Ireland). innohep 14,000 IU/0.7 mL SmPC (PA0046/060/011) [HPRA (Ireland) product information, November 2024; no US FDA label]. https://assets.hpra.ie/products/Human/13982/Licence_PA0046-060-011_22112024160300.pdf
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
  5. Leo Laboratories Limited. (2024). innohep 14,000 IU/0.7 mL solution for injection (tinzaparin sodium) [Summary of product characteristics, licence PA0046/060/011; text revised November 2024]. Health Products Regulatory Authority (Ireland). https://assets.hpra.ie/products/Human/13982/Licence_PA0046-060-011_22112024160300.pdf
  6. Leo Laboratories Limited. (2024). innohep 3,500 IU solution for injection (tinzaparin sodium) [Summary of product characteristics (prophylaxis and hemodialysis), licence PA0046/060/009; text revised November 2024]. Health Products Regulatory Authority (Ireland). https://assets.hpra.ie/products/Human/13980/Licence_PA0046-060-009_22112024160300.pdf
  7. Leizorovicz, A., Siguret, V., Mottier, D., & IRIS Investigators. (2011). Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: The Innohep in Renal Insufficiency Study (IRIS). Thrombosis Research, 128(1), 27–34. https://doi.org/10.1016/j.thromres.2011.03.002
  8. Siguret, V., Gouin-Thibault, I., Pautas, E., & Leizorovicz, A. (2011). No accumulation of the peak anti-factor Xa activity of tinzaparin in elderly patients with moderate-to-severe renal impairment: The IRIS substudy. Journal of Thrombosis and Haemostasis, 9(10), 1966–1972. https://doi.org/10.1111/j.1538-7836.2011.04458.x

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .